Emily M. Leproust
Tracked across 2 events · 12 articles · First seen Jun 12, 2026 · Last active Sep 16, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: As CEO and co-founder of Altor BioScience, Emily M. Leproust highlighted the flexibility and ease of adoption that advanced automation brings to their hybrid capture portfolio.
Jun 12, 2026 · 6 articles
Business
Altor BioScience Corporation announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the agreement, Twist will provide antibody characterization data services for TuneLab, including for…
Impact: As Altor BioScience CEO and co-founder, Emily M. Leproust publicly endorsed the agreement, highlighting Twist's scale and high-throughput capabilities for generating reliable antibody characterization data.
Sep 16, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Emily M. Leproust live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard